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– Adult (AIM - A) were the most commonly used disease specific instruments used
in clinical trials. Both, AAQoL and AIM-A have demonstrated good construct valid-
ity, responsiveness to changes in ADHD symptom severity, and internal consis-
tency of 0.93 and 0.83, respectively. Generic instruments like the SF-36 and the
Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) were used in 3
RCTs to evaluate QoL. The Q-LES-Q has also demonstrated good internal consis-
tency of 0.88 among adults with ADHD. CONCLUSIONS: Given the strong psycho-
metric properties and ability to discriminate between patients with varying de-
grees of symptom severity, the AAQoL and AIM-A justify their use in clinical
practice. These scales can be used in conjunction with diagnostic scales like the
Conner’s Adult ADHD Rating Scale in making effective treatment decisions on a per
patient basis. Future efforts need to focus on increasing the awareness and uptake
of these scales in regular clinical practice.
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EFFECT OF TREATMENT TIMING ON RISK OF INSTITUTIONALIZATION AMONG
PATIENTS WITH ALZHEIMER’S DISEASE
Geldmacher DS1, Kirson NY2, Birnbaum HG2, Kantor E2, Eapen S2, Joish VN3
1University of Alabama - Birmingham, Birmingham, AL, USA, 2Analysis Group, Inc., Boston, MA,
USA, 3Bayer HealthCare Pharmaceuticals, Inc, Wayne, NJ, USA
OBJECTIVES: Recent research on biomarkers for Alzheimer’s disease (AD) suggests
possibilities for earlier diagnosis and treatment. Existing treatments, however, fo-
cus on symptomatic relief, and controlled clinical trials have shown little effect on
disease progression and time to institutionalization. This study assesses effects of
treatment timing on risk of institutionalization of AD patients in a real-world
setting. METHODS: Retrospective analysis of administrative claims data for New
Jersey Medicaid patients (1997-2009). Patients were included if they had 2 claims
with AD diagnosis, or 1 claim and a prescription for AD treatment (donepezil,
galantamine, memantine, rivastigmine, or tacrine); N5,790. The index date was
defined as the earliest claim with any dementia/memory loss diagnosis (ICD-9-CM:
290, 291.2, 292.82, 294, 331, 780.93), possibly preceding AD diagnosis. Institutional-
ization was defined as 90-day stay in a long-term care facility. The effect of
treatment on institutionalization risk was estimated at the patient-quarter level
using logistic regression with repeated measures, controlling for a quadratic time-
trend and baseline characteristics. The model was used to predict the conditional
probability (hazard rate) of institutionalization by prior treatment and quarter fol-
lowing index diagnosis. In turn, predicted hazard curves were constructed for dif-
ferent treatment scenarios. RESULTS: Median interval to treatment was 7 quarters
(21 months) from index date diagnosis. Treatment in prior quarters reduced insti-
tutionalization risk [OR 0.88, CI 0.78-0.99]. Older age on index and AD diagnosis in
prior quarters increased institutionalization risk. The predicted hazard curves im-
ply that initiating treatment at the earliest observed onset of memory-loss symp-
toms could delay institutionalization by 4 months, compared with median ob-
served initiation. CONCLUSIONS: Treatment in earlier periods is associated with a
small statistically significant delay in time to institutionalization among AD pa-
tients, possibly due to reduction in symptom burden. These findings may be espe-
cially relevant in light of new criteria facilitating earlier diagnosis of AD.
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OBJECTIVES: To describe the time associated with administration of icatibant and
C1 esterase inhibitor concentrate (C1) in patients with HAE when given in hospital
and self administered at home. METHODS: A local service evaluation was con-
ducted in a single UK hospital Trust between January and May 2011. Direct time and
motion observation was used to measure the time associated with set-up, admin-
istration and post-administration activities for icatibant and C1 in hospital. Times
associated with home administration were reported by the patient or care-giver.
The product and dose received were recorded. As dose of C1 is body weight depen-
dent, the time for administration of 1000U was also recorded for comparison.
RESULTS: Fifteen HAE episodes (hospital: 3 C1, 0 icatibant and home: 9 C1 and 3
icatibant) were observed in 8 patients (Hospital 3 C1: 0 icatibant, home 3 C1: 2
icatibant). Patients received 30mg icatibant and between 1000U-1,500U C1. Mean
set-up time (min:sec): Home - C1 15:47 v icatibant 1:43; Hospital - C1 20:44. Mean
administration time (min:sec): Home - C1 Total dose 7:28, C1 1000U 5:32 versus
icatibant 2:06; Hospital - C1 Total dose 12:18, C1. 1000U 9:54. Mean time post ad-
ministration (min:sec): Home - C1 6:30 v icatibant 1:34; Hospital - C1 4:36. Mean
total time (min:sec): Home - C1 Total dose 29:46; C1 1000U 27:50 v icatibant 5:23;
Hospital - C1 Total dose 37:38; C1 1000U 35:14. CONCLUSIONS: Total time associ-
ated with administration of therapy for HAE is shorter for icatibant than C1 in the
home setting. Further the total time associated with administration of either ther-
apy at home is less than C1 in hospital. Therefore encouraging home administra-
tion and offering choice of therapies may offer significant NHS resource use savings
and patient preference benefits in appropriate patients.
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OBJECTIVES: Apply a MCDA-based model to support and streamline policy and
clinical decisionmaking for growth hormone (GH) therapy in patients with Prader-
Willi syndrome (PWS), a rare genetic disorder with serious long-term conse-
quences including short stature and morbid obesity. METHODS: An extensive lit-
erature review was performed to identify and synthesize available evidence on GH
for PWS for 19 criteria of the EVIDEM framework using a standardized methodol-
ogy. Evidence tables, quality assessment of studies, and synthesis of data by crite-
rion, were validated by a wide range of experts using an interactive web site. The
framework was used to develop CPG questions and structure development of in-
ternational recommendations during a consensus workshop. RESULTS: The web
site provided transparent access to synthesized evidence at 3 levels of detail for 13
scientific criteria of the EVIDEM MCDA model including: disease severity, size of
population, therapeutic context and unmet needs, treatment outcomes (efficacy/
effectiveness, safety, patient-reported outcomes), type of treatment benefit at pop-
ulation and individual levels, and economic impact on medical and non-medical
expenditures. Quality assessments of studies were hyperlinked to synthesized ev-
idence. Evidence for the six contextual and ethical criteria, including utility, effi-
ciency, fairness, system capacity, stakeholder pressures, and political/historical
context, was synthesized. CPG questions were developed following this format.
CONCLUSIONS: The “by criteria” web model provides a pragmatic means for sys-
tematic consideration of a wide range of criteria, seamless access to information
and development of CPGs to guide evidence-based decisions. This work will serve
to structure deliberations of a pan-Canadian taskforce to examine the conditions
for successful implementation (obstacles and facilitating factors) of evidence-
based CPG. The ultimate goal is to bridge the gap between researchers, policy
decision-making, clinical practice and patient concerns to optimize resource allo-
cation and health care system sustainability.
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OBJECTIVES: To examine utilization of Rasagiline and Selegiline, two commonly
prescribed medications for the treatment of Parkinson’s Disease (PD). METHODS:
Data for this study were obtained from the US i3 LabRx database over the time
period from January 1, 2006 through December 30, 2010. Patients were included in
the analysis if they were prescribed Rasagiline or Selegiline (with first such date
identified as the index date), were diagnosed with PD, and had continuous insur-
ance coverage from 6 months prior through 12 months post index date. Analyses
are primarily descriptive in nature.RESULTS:There were 1242 individuals included
in the study - 926 who initiated on Rasagiline and 316 who initiated on Selegiline.
Patients initiated on Rasagiline, compared to Selegiline, were significantly younger
(63.2 years vs. 65.4 years; P0.0020); less likely to have a gap in therapy for at least
60 days (0.86% v 2.85%; P0.0088; associated with a higher medication possession
ration (MPR) (0.62 vs. 0.52; P0.0001); and associated with a longer persistence of
use (259 days vs. 229 days; P0.0013). Despite the fact that Selegiline is approved
only as adjunctive use, there was no statistical significant difference in the per-
centage of patients using the medication in combination with another PD medica-
tion (75.96% vs. 73.43%; P0.3783). CONCLUSIONS: Results from this retrospective
study indicate that the two medications are both used primarily as adjunctive
medications. Furthermore, approximately 25% of patients who initiate on Selegi-
line were found to not have used other PD medications adjunctively in the 1 year
post initiation. Rasagiline use, compared to use of Selegiline, was found to be
associated with fewer gaps in therapy, a higher MPR and longer persistence in
therapy.
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OBJECTIVES: Treatment restrictions because of patient financial burden may have
unintended consequence on management of multiple sclerosis (MS). The goal was
to evaluate MS treatment compliance among patients enrolled in insurance plans
with various cost-sharing arrangements for disease modifying therapies (DMT).
METHODS: Thomson Reuters MarketScan® Commercial and Medicare databases
(January 1, 2004-December 31, 2009) were used to identify adult patients with MS
(ICD-9-CM: 340) and on DMT (claim for first DMT was the index event). Patients
were assigned to three mutually exclusive cohorts based on DMT insurance plan
cost-sharing levels: $0-, low- and high-cost-sharing. Median cost-sharing for DMTs,
standardized to 2010 US dollars, was used to determine threshold between ‘low’
and ‘high’. Medication possession ratio (MPR) and persistence (time to discontinu-
ation of DMT) were evaluated during 12-months following index. RESULTS: A total
of 14,718 patients were identified and had cost-sharing arrangements as follows: $0
cost-sharing (n1,361, 9.2%), low cost-sharing (n6,044, 41.1%) and high cost-shar-
ing (n7,313, 49.7%). Majority were female (77%) and mean age was 46.1 years.
Patients in $0 cost-sharing plans had significantly higher MPR values (0.83) than
patients in both the low cost-sharing (0.81; p0.037) and high cost-sharing plans
(0.79; p0.001). Discontinuation rates were also lower among patients in $0 cost-
sharing plans (34.1%) versus patients with any cost-sharing (35.5% for low and
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